Abstract. Hepatocellular carcinoma (HCC) is a highly lethal primary liver malignancy characterized by hypoxia, a common feature of solid tumors, particularly in HCC. Hypoxia-inducible factors (HIFs) ...
AbstractBackground:. JS107 is a monomethyl auristatin E conjugated, CLDN18.2 specific ADC. JS107 exhibited potent anti-tumor activities in preclinical studies with a tolerable safety profile. Here we ...
Cancer Res (2025) 85 (8_Supplement_2): CT053. A total of 624 patients were randomized to aumolertinib plus chemotherapy (n=310) or aumolertinib monotherapy (n=314) and stratified according to EGFR ...
BACKGROUND: BTK, a non-receptor kinase in the B-cell receptor signaling pathway, plays an essential role in B-cell development and differentiation. BTK is critical for malignant B-cell survival. Oral ...
Background: The current standard of care for patients (pts) with treatment-naive Stage II–III triple-negative breast cancer (TNBC) is neoadjuvant pembrolizumab ...
You do not currently have access to this content.
Abstract. Breast cancer represents the most commonly diagnosed female malignancy worldwide. Although breast cancer screening and treatments have improved significantly over the last half-century, ...
Cancer Res (2024) 84 (7_Supplement): LB236. Background: The undeniable success of CD19 CAR-T cell therapy in managing relapsed or refractory (r/r) B-cell hematological malignancies, such as diffuse ...
Abstract. The 5-year survival rate for stage 4 advanced cancer is 5.8% for stomach cancer, 17% for colon cancer, 8.4% for lung cancer (NSCLC), 4.4% for liver cancer and 38.6% for breast cancer, 5.1% ...
AbstractIntroduction and Objectives:. 2141-V11 is a novel anti-CD40 antibody developed by our group, with enhanced binding to FcγRIIB that results in effective tumor-specific T-cell responses in vivo ...
Abstract. ADAM9 (A Disintegrin And Metalloproteinase 9) is a transmembrane metalloproteinase overexpressed in a wide range of solid tumors, where it promotes tumor progression, metastasis, and poor ...
Introduction: Engineered cell therapies have demonstrated significant clinical activity against hematologic malignancies, but responses have been rare in solid tumors. Our previously developed human ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results